Fludarabine exposure leads to impaired peripheral blood stem cell (PBSC) mobilization in indolent lymphoproliferative disorders (LPD). We previously reported that only 34% of fludarabine-exposed patients mobilized successfully using granulocyte-colony stimulating factor (G-CSF; median 10 lg/ kg/day) with or without chemotherapy, with unpredictable kinetics and moderate infectious morbidity. Stem cell factor (SCF) plus high-dose twice daily (b.d.) G-CSF may improve mobilization in these patients. SCF 20 lg/kg/day subcutaneously was given from day 1, G-CSF 12 lg/kg b.d. subcutaneously from day 4, apheresis commenced from day 6. Previous study patients served as historical controls. Thirty five patients with indolent LPD were enrolled, median age was 54 years (range 31-66), 66% male, median cumulative prior fludarabine dose was 660 (405-900) mg. Overall, 22 patients (63%) collected X2.0 Â 10 6 /kg PBSC (success), compared to 34% controls (odds ratio (OR) 3.2; 95% confidence interval (CI) (1.2, 9.3); P ¼ 0.021). Median CD34 þ yield overall was 2.3 Â 10 6 / kg (0.53-8.97) from median four (2-6) aphereses. Study patients X50 years mobilized successfully more frequently than controls (58 versus 17%; P ¼ 0.0065). Adjusting for age, successful mobilization remained significantly higher in the current study (OR 4.2; 95% CI (1.4, 14.0); P ¼ 0.008). SCF/high-dose b.d. G-CSF improves PBSC mobilization efficacy after fludarabine exposure, over mobilization using G-CSF as the mobilizing cytokine. This combined growth factor strategy is a preferred mobilization method for fludarabine-exposed patients.
Introduction
Impaired peripheral blood stem cell (PBSC) mobilization affects 20-30% of all cancer patients, and is particularly prevalent in patients with indolent lymphoproliferative disorders (LPD). 1 Failed mobilization significantly hampers the treatment of patients with these disorders where, with careful patient selection, high-dose therapy and reinfusion of autologous PBSC can achieve disease-free and overall survivals of 42 and 66% respectively at 8 years, in patients with indolent non-Hodgkin's lymphoma (NHL), 2 and complete response rates of up to 80%, and overall survival of 40-80% in patients with chemotherapysensitive chronic lymphocytic leukemia (CLL). 3 The antimetabolite nucleoside analog fludarabine is widely used for the treatment of CLL, yielding superior remission rates and freedom from progression. 4, 5 Although fludarabine is less extensively evaluated in the setting of indolent NHL, it remains an important treatment option for patients with alkylatorrefractory disease. 6 Earlier exposure to fludarabine is associated with impaired PBSC mobilization using conventional regimens, with mobilization failure rates of over 60% in patients with indolent LPD. 7 The magnitude of this clinical problem is increasing as utilization of fludarabine treatment increases in both CLL [8] [9] [10] [11] and indolent lymphoma. [12] [13] [14] [15] We postulate that combining the conventional mobilizing cytokine granulocyte-colony stimulating factor (G-CSF, filgrastim) with other cytokines, for example stem cell factor (SCF, ancestim) could lead to improved mobilization in fludarabineexposed patients. SCF is a glycosylated protein whose class III tyrosine kinase receptor, c-kit, is found on many cells including early to more mature haemopoietic progenitor cells, mast cells and primordial germ cells, some acute myeloid leukemic blast cells, but importantly not on malignant cells in LPDs. 16 When used alone in vitro, SCF has only minimal effects, mainly stimulating the growth of neutrophil colonies, 16 however it synergizes with G-CSF to stimulate growth of erythroid, megakaryocytic and granulocytic colony growth, and improved progenitor cell growth in culture has led to incorporation of SCF in many protocols for ex vivo progenitor cell expansion. 17 Stem cell factor alone is not a potent stimulus to mobilize PBSC, however mobilization synergy between SCF and G-CSF has been noted in mice, dogs and non-human primates, increasing the absolute number of PBSC mobilized, as well as leading to superior repopulating ability of progenitor cells when administered to lethally irradiated recipients. [18] [19] [20] [21] Initial phase I trials of SCF in humans noted increased mobilization of granulocyte/macrophage colony-forming units. Randomized studies of SCF plus G-CSF mobilization in breast and ovarian cancer patients showed apheresis yields that were increased two-to threefold, at SCF doses ranging from 5-25 mg/ kg/day, with or without chemotherapy, compared to mobilization with G-CSF alone. 22, 23 In a randomized phase III study of myeloma patients, chemotherapy/SCF/G-CSF allowed a reduced number of leukaphereses (median 1 versus 2, P ¼ 0.0007) to achieve the target collection of 45 Â 10 6 /kg CD34 þ cells, versus chemotherapy/G-CSF alone. 24 Mobilization in breast cancer patients using the SCF plus G-CSF combination is also successful. 25 One study of high-risk breast cancer patients resulted in successful mobilization in 63% of patients, compared with 47% of patients mobilized with G-CSF alone (Po0.05). 22 None of these earlier studies have specifically explored the possible utility of SCF with G-CSF in fludarabineexposed patients.
In this study, we investigate a novel mobilization regimen using SCF plus high-dose twice daily (b.d.) G-CSF for PBSC mobilization in patients with indolent LPD and earlier fludarabine exposure, showing improved mobilization success in this poor mobilizer patient population.
Materials and methods

Patient eligibility and study design
Patients older than 16 years with a diagnosis of indolent LPD, including 'low grade' NHL and CLL, with exposure previous to fludarabine, considered suitable for collection and storage of PBSC before planned or possible autologous transplantation, ECOG performance status of o3, and life expectancy of 46 months were eligible for this study.
Exclusion criteria included cytokine exposure within 10 days before the commencement of study drug, severe symptomatic asthma, a history of severe allergy or anaphylaxis, known sensitivity to Escherichia coli-derived proteins, significant cardiac or liver disease, uncontrolled infection or human immunodeficiency virus seropositivity, pregnancy or breastfeeding.
The study protocol was approved by the institutional Ethics Committee, and all patients provided written informed consent.
A previously published historical control cohort of 41 patients with indolent LPD and previous exposure to fludarabine was assessed previously for success of PBSC mobilization using G-CSF as the mobilizing cytokine (various regimens, described in Results section), and for correlation of mobilization with various known risk factors. 7 Patients enrolled in this study underwent mobilization between April 2003 and April 2006, at Peter MacCallum Cancer Centre.
Study medications and definitions
The mobilization strategy in this study constituted SCF (r-metHuSCF; ancestim; Stemgen, Amgen Inc., Thousand Oaks, CA, USA) 20 mg/kg/day starting on day 1, plus high-dose b.d. G-CSF (r-metHuG-CSF; filgrastim; Neupogen, Amgen Inc.) 12 mg/kg b.d. starting on day 4. Because of the potential for mast cell degranulation and allergic reactions with SCF injection, 26 all patients were administered H1 and H2 antihistamines cetirazine 10 mg/day and ranitidine 300 mg/day (commencing 12-24 h before first SCF injection) and salbutamol 200 mg/day; each premedication administered 60-90 min before each SCF injection. Premedications continued daily until 48 h after last SCF dose. Drug administration continued on a daily basis until completion of apheresis or failure of mobilization. From the commencement of apheresis G-CSF was administered nightly at 24 mg/kg, to avoid potential interference with the morning apheresis procedure. Patients underwent daily apheresis of 1.5 total blood volumes on a Cobe Spectra Apheresis System. Apheresis was scheduled from day 6, provided that the peripheral blood (PB) CD34 þ count was X2 Â 10 6 /l. The outcome of the mobilization attempt was classified as the following:
(1) successful if X2 Â 10 6 /kg CD34 þ cells were collected (2) suboptimal if o2 Â 10 6 /kg CD34 þ cells were collected, or (3) unsuccessful if apheresis was not attempted due to low levels of PB CD34 þ cells after treatment with study drugs.
Leukapheresis continued either until mobilization success or until a maximum of five leukaphereses were completed, whichever came first.
Laboratory analysis of leukapheresis product
Reference vials were thawed on a representative sample from the study group, consisting of two suboptimal mobilizers, two successful mobilizers and two very successful mobilizers with 45 Â 10 6 CD34 þ cells/kg. Granulocyte/macrophage colonyforming unit assays were performed as previously described. 27 Flow cytometry was also performed on the reference vials from the six representative patients, and CD38 expression and c-Kit expression on CD34 þ PBSCs were examined. The method is as follows: reference vials were rapidly thawed at 37 1C, 10 ml cells added to 10 ml of CD38 FITC (BD clone HB-7), 10 ml of CD34 PE (BD clone 8G12), 10 ml of CD45 PerCP (BD Clone 2D1) and 5 ml CD117 APC (BD Clone 104D2). Cells were incubated for 15 min in dark at room temperature. After incubation, 1 ml of phosphate-buffered saline was added to tubes and then run on four color BD FACSCalibur without lysing or cell washing. Results were then analyzed using Cytomics RXP software, PBSCs were gated on CD34 v log SSC, and CD34 and CD117 expressions were assessed on the gated CD34 þ cells. 7AAD was included in a separate tube to assess viability.
Statistical methods
The sample size of 35 allowed for a power of at least 80% to detect a significant difference between the mobilization success rate in this study compared to historical controls, assuming the true success rate in this study was more than 65%. Tests carried out were two-sided with a significance level of 0.05, performed using the StatXact (StatXact 7, CYTEL Software Corporation, Cambridge, MA, USA, 2005), LogXact (LogXact 7, CYTEL Software Corporation, 2001) and SPSS software (SPSS for Windows Release 14.0.0 SPSS Inc., Chicago, IL, USA, 2005). Confidence intervals (95% CI) for percentages were computed using an exact method based on the binomial distribution. Comparison of this study and historical controls comprised the following: logistic regression for analyzing the percentage of success rates in both adjusted and unadjusted analyses; Fisher exact test, Cochran-Armitage test for trend and the Wilcoxon test (whichever applicable) for analyzing baseline characteristics and the number of apheresis required to reach 42 Â 10 6 cells/ kg. Logistic regression and multiple linear regression models built using a stepwise procedure were used to identify factors that were predictive of successful mobilization and the final yield of CD34 þ cells. It was recognized that the former model may result in loss of information due to dichotomization of the data and hence, the reduction of statistical power.
Primary end points for this study were (a) the proportion of patients in this study with a successful PBSC collection on their first mobilization attempt and (b) a comparison of mobilization efficacy between this study regimen and historical controls. Secondary end points for this study were (a) the number of leukapheresis procedures required to reach a yield of X2 Â 10 6 / kg CD34 þ cells in this study versus historical controls, (b) predictive factors for successful mobilization using high-dose BD G-CSF plus SCF in this study and (c) toxicity data for this mobilization regimen.
Results
Patient characteristics
Patient characteristics for baseline demographics were collected on all patients in this study and compared to historical controls (Table 1) .
For the historical control group, 41 patients mobilized for indolent LPD between January 1996 and November 2002 with exposure to fludarabine underwent a total of 54 mobilization attempts (due to the failure rate of initial mobilization attempt) mobilized with: G-CSF alone (n ¼ 8), G-CSF 5-12 mg/kg/day with 20 mg/kg/day SCF (n ¼ 1), cyclophosphamide plus G-CSF (n ¼ 35), cyclophosphamide plus G-CSF (5-14 mg/kg/day) plus SCF (n ¼ 4) or G-CSF plus another chemotherapy regimen (n ¼ 6) as previously published. 7 Patients in this study were well matched compared to historical controls for age, sex, baseline platelet count, time since diagnosis and earlier chemotherapy toxicity score (calculated as per the method described by Drake et al. 28 Compared to the control group, this study group had a higher incidence of CLL/PLL (prolymphocytic leukemia) compared to indolent NHL histology (lymphoplasmacytic, splenic marginal zone or follicular lymphoma P ¼ 0.022), a higher hemoglobin level, a higher cumulative fludarabine dose exposure and a longer time since last fludarabine exposure (Table 1) . Sixty-nine percent of patients were in complete remission at the time of mobilization, and patients in this study had a lower incidence of bone marrow involvement (21 versus 53%, P ¼ 0.0068); however, 24% had mild-to-severely hypocellular bone marrow morphology. No patients in either the study group or the historical controls had previously attempted PBSC collection.
Mobilization kinetics and efficacy
Mobilization kinetics were predictable; 24 patients (69%) commenced apheresis as scheduled on day 6, with the remainder (n ¼ 11; 31%) commencing on day 7 or 8. A median of four apheresis procedures was performed (range 2-6). No patients were unsuccessful (failed to commence apheresis due to inadequate PB CD34 þ counts). The median CD34 þ yield was 2.3 Â 10 6 /kg (range 0.53-9.0). Overall, 22 patients (63, 95% CI: 45, 79%) had successful collection compared to 14 (34%) of historical controls ( Table 2) .
As increasing age was a risk factor for failed mobilization in earlier analysis of the historical controls, 7 subgroup analysis was performed in patients o50 and X50 years of age. In the younger group, total CD34 þ cells/kg collected was similar between this study and historical controls. In the older age group, this study was associated with a higher median collection. Adjusting for age, this study was associated with a significantly higher absolute CD34 þ cell collection (P ¼ 0.0001).
Overall, the odds ratio (OR) for successful collection (X2 Â 10 6 /kg CD34 þ ) on this study relative to historical controls was 3.2 (95% CI: 1.2, 9.3; P ¼ 0.021) ( Table 3 ). Within the age subgroups, the older age group experienced significantly higher likelihood of mobilization success compared to historical controls (OR 6.7; 95% CI 1.6, 35.6; P ¼ 0.0065, Table 3 , Figure 1 ) and there was no significant difference between successful mobilization in the younger group (OR 1.8; 95% CI 0.29, 14.6; P ¼ 0.69). After adjusting for age, the OR for successful mobilization remained significantly in favor of this study (P ¼ 0.0082, Table 3 ).
Analysis was repeated adjusting for age and other baseline characteristics that were significant when comparing the patients of this study versus historical controls. After adjusting for age, time since fludarabine was administered previously, cumulative prior fludarabine dose, bone marrow involvement, CLL/PLL histology and hemoglobin level, a significant difference in mobilization success rates remained in favor of this study protocol compared with historical controls (P ¼ 0.031). Figure 1 Median CD34 þ cell total collection (horizontal bars) stratified for age group: age o50 and X50 years. *P-values are for binary comparison of successful versus suboptimal mobilization (cutoff 2 Â 10 6 CD34 þ per kgFdashed line) within these age groups comparing historical controls to this study group. Nine patients in the historical control group failed to achieve adequate peripheral blood CD34 þ counts to undergo apheresis. The total number of CD34 þ cells collected was assumed to be 0 for each of these patients.
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All patients in this study were able to commence apheresis; however, nine patients from the historical control group failed to mobilize adequate numbers of CD34 þ cells to commence apheresis. Of those patients able to commence apheresis and achieving 42 Â 10 6 /kg CD34 þ cells, there was no significant difference in the number of leukapheresis procedures required to achieve yields of X2 Â 10 6 /kg CD34 þ cells between this study and historical controls.
Predictive factors for mobilization success
Multifactorial analysis was conducted in two ways: first, using outcome (CD34 þ yield) as a binary variable dichotomizing at 2 Â 10 6 /kg CD34 þ cells, and second, as a continuous variable. A higher hemoglobin level was associated with higher CD34 þ count in the continuous analysis (P ¼ 0.007), but not in the binary analysis. Shorter time from last fludarabine course to mobilization was associated with mobilization success in both binary and continuous analyses (P ¼ 0.029 and Po0.0005, respectively; Table 4 ).
Incorporating CD34 þ yield on day 1 as an additional factor in the multifactorial analysis, CD34 þ yield on day 1 predicted independently and significantly for a favorable outcome both on binary and continuous analyses (P ¼ 0.005 and Po0.0005, respectivelyFdata not shown). Similarly, indolent NHL histology (as opposed to CLL/PLL histology) predicted for mobilization success as well as absolute CD34 þ yield (P ¼ 0.014 and 0.006Fdata not shown). Time since last fludarabine was a significant predictor in the continuous analysis (Po0.0005) but not in the binary analysisFdata not shown.
Adverse events
The treatment was well tolerated. The commonest adverse event was bone pain (n ¼ 15; 43%); the majority grade 1 (n ¼ 9; 26%) or grade 2 (n ¼ 6; 17%). Injection site reaction was reported in 40% of patients (n ¼ 14), the majority being grade 1, with one patient reporting grade 2 severity (3%). Other common adverse events were injection site reaction (n ¼ 15, 43%, grade 1-2), lethargy (n ¼ 4, 11%, all grade 1), allergic reaction (n ¼ 2, 6%, all grade 1), allergic rhinitis (n ¼ 2, 6%, all grade 1) and pigmentation changes (n ¼ 2, 6%, all grade 1). Only one case of Table 2 Proportions of patients in this study with successful and suboptimal collection on mobilization with SCF and high-dose G-CSF Abbreviations: SCF, stem cell factor; G-CSF, granulocyte-colony stimulating factor. 
Qualitative analyses of mobilized cells
The study regimen mobilized leukocytes and granulocytes efficiently, with no significant differences between the mobilization of total leukocytes and granulocytes, between the study group or the historical controls (data not shown). There was also no difference in the pattern of leukocyte or granulocyte mobilization between successful and unsuccessful mobilizers.
To assess the likely quality of cells mobilized with the SCF/highdose G-CSF regimen, thawed apheresis PBSCs were assessed for CFU potential and CD34 þ /CD38 À content. As expected, the granulocyte/macrophage colony-forming potential correlated closely with both the PB CD34 þ count (r ¼ 0.9, P ¼ 0.01) and the yield of CD34 þ cells collected (r ¼ 0.98, P ¼ 0.0004). A qualitative analysis of the CD34 þ /CD38 À content of the thawed apheresis product showed a bimodal distribution of CD38. Approximately half of the PBSCs were CD34 þ /CD38 À , and half were CD34 þ /CD38 þ . The c-Kit was negative on the majority of PBPCs analyzed (data not shown).
With respect to engraftment potential of these cells, only nine study patients have thus far undergone transplantation, with a median time to neutrophil engraftment of 11 days (range 6-16 days), and a median time to platelet engraftment of 14 days (range 11-24 days) in seven of nine patients. One further patient engrafted neutrophils, but remained platelet dependent for 2 months until the time of his death from infectious complications. The ninth patient remained platelet dependent for over 3 months post-transplant, due to possible immune thrombocytopenic purpura. These data are difficult to interpret in the light of such small numbers.
Discussion
Successful mobilization of PBSC in patients with earlier fludarabine exposure is often unacceptably low, 29, 30 particularly in patients with indolent LPD and fludarabine exposure, where success is as low as 34%. 7 The precise mechanism of this effect may involve both stem cell toxicity as well as stromal injury by fludarabine.
Granulocyte-CSF mobilizes PBSC at least in part due to its ability to increase active neutrophil proteases in the bone marrow extracellular fluid, which cleave adhesion molecules between PBSC and the stroma. 31, 32 SCF may synergize with G-CSF, particularly increasing proteases that cleave the adhesion molecule VCAM-1 on marrow stromal cells, thereby disrupting PBSC binding through the b1-integrin VLA-4 expressed on their surface. 33 'Poor mobilizers' represent a particularly refractory patient group for whom alternative mobilization strategies are keenly sought. In a previous study of failed mobilizers, remobilization was attempted using their earlier regimen (filgrastim 10 mg/kg/ day or filgrastim 5-10 mg/kg/day plus chemotherapy), with the addition of SCF 20 mg/kg/day. This strategy improved mobilization success to 54% in patients who had failed filgrastim-alone mobilization and 45% in patients who had previously failed filgrastim plus chemotherapy mobilization. 34 This study assessed the routine application of a novel SCF/ G-CSF mobilization regimen in fludarabine-exposed patients with indolent LPD, and showed 63% mobilization success, compared to 34% in a similar group of historical controls. 7 Although numbers of patients are limited, qualitative analysis of engraftment data on the subset of patients who have been transplanted, as well as CFU potential and CD34 þ /CD38 À PBSC content of thawed apheresis product on a representative sample of unsuccessful, successful and highly successful mobilizers shows adequate content of stem and progenitor cells within the mobilized product.
In our historical controls, the likelihood of mobilization success using conventional regimens in fludarabine-exposed patients decreased with increasing age. Although age had not Stem cell factor and twice daily filgrastim for PBSC mobilization KE Herbert et al been previously found to be predictive of mobilization efficacy in studies of non-fludarabine-exposed patients, 1, 28, 29, 35 this study postulated that age may increase susceptibility to the toxic effects of fludarabine on the bone marrow. This study suggests that the older group of fludarabine-exposed LPD patients may benefit most from the SCF/high-dose G-CSF regimen, as the greatest improvement in success rates occurred in patients aged 50 years and over. Importantly, the improved success rates using this study mobilization regimen remained significant after adjusting for age (age-adjusted OR for mobilization success using SCF/high-dose G-CSF was 4.2, 95% CI 1.4, 14.0; P ¼ 0.0082). Some studies including our own historical control group report no impact of the interval between last fludarabine exposure and likelihood of successful mobilization 7,36 contradicting others showing better mobilization with a greater interval from the last dose of fludarabine or other chemotherapy. 1, 37 This study showed a higher rate of mobilization success with a shorter time interval from last fludarabine course. Note that the median time interval from the last fludarabine course in this study was 7.1 months compared to 2.2 months in the historical controls; however, significance remained after correcting for this factor. The lower incidence of bone marrow involvement with disease in this study compared to historical controls (21 versus 53%, P ¼ 0.0068) may have improved mobilization efficacy, however significance also remained after adjustment for this factor (P ¼ 0.031).
Baseline anemia was associated with mobilization failure in both historical controls and patients in this current study. Similar to the association between baseline thrombocytopenia and poor mobilization in other studies, 29, 34, 38 anemia possibly functions as a surrogate marker of bone marrow toxicity after fludarabine.
Past exposure to chemotherapy or radiotherapy are often predictive factors for mobilization efficacy. 28, 39 Only two patients in our study had received radiation; an insufficient number to test this as a predictive factor. The cumulative toxicity score of previous chemotherapy was not significantly different between successful and suboptimal mobilizers in this study. The lack of predictive effect of the cumulative chemotoxicity score was also seen in our historical controls, supporting the notion that fludarabine exposure exerts far more negative influence on mobilization efficacy than exposure to other chemotherapeutic agents combined. 7 Stem cell factor plus high-dose b.d. G-CSF resulted in predictable mobilization kinetics; the majority of patients commenced apheresis as scheduled on day 6 of treatmentFa feature that facilitates scheduling and resource utilization.
Although nine patients in the historical controls failed to commence apheresis due to inadequate blood CD34 þ counts, all of the patients in this study achieved adequate CD34 þ counts for commencement of collection. The threshold for commencing apheresis used in this study was low (2 Â 10 6 /l CD34 þ cells), in recognition that fludarabine-exposed patients may not have achieved higher 'traditional' threshold CD34 þ counts for apheresis. A previous study had shown that for a given CD34 þ count, linear increases in apheresis yield were notable even at blood CD34 þ levels of 2 Â 10 6 /l. 40 Although the high dose of G-CSF itself may have provided some benefit in this study, numerous studies show that a high dose of G-CSF itself may not substantially improve mobilization in poor mobilizers. A study on previously failed mobilizers showed that remobilization using high-dose G-CSF (16 mg/kg b.d.) only slightly improved mobilization outcome 41 with many patients requiring a third mobilization to achieve adequate cells for transplantation. The addition of SCF to regular (5-10 mg/kg) doses of G-CSF has been shown in a previous study to improve mobilization in earlier failed mobilizers. 34 Another study showed that in heavily pretreated patients who failed mobilization using a relatively high baseline dose of G-CSF (10 mg/kg b.d.), 38% went on to achieve successful collection using SCF plus G-CSF 10 mg/kg b.d.Fa regimen similar to our own. 38 Taken together, these data plus our own study indicate that there are incremental gains in efficacy to be made in poor mobilizers, both by increasing the dose of G-CSF and by adding SCF for synergy.
One potential weakness in a study of this size is the degree of comparability between the two groups. Patients in this study had a longer time since last fludarabine exposure, a higher cumulative fludarabine dose, a lower proportion of non-CLL/ PLL patients and a lower incidence of bone marrow involvement. Whether these factors contributed to the better mobilization efficacy of the study regimen would be answered in a larger study, however our analysis indicates that mobilization tended to be better overall with a shorter time since last fludarabine exposure, and adjustment for each of the other variables did not negate the overall statistical benefit of this study regimen for PBSC mobilization.
The mobilization regimen using SCF plus high-dose b.d. G-CSF was well tolerated. Bone pain and injection site reaction were the commonest reported adverse events, the latter with an incidence similar to previous reports. 24, 38 There have been numerous reports of splenic rupture in the literature related to the use of filgrastim [42] [43] [44] or pegylated filgrastim, [45] [46] [47] and although routine ultrasound was not performed in study patients, there was no clinical evidence of abdominal pain or anemia, and no increase in bone pain compared to historical controls, during close clinical follow-up of all participants on this study.
Although patients with indolent LPD and earlier fludarabine exposure are notoriously difficult to mobilize successfully, we conclude that mobilization can be significantly improved using a combination of SCF plus high-dose b.d. G-CSF.
